Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of Efficacy and Safety of Immune Check Point Inhibitors in Hepatocellular Carcinoma Patients in Ain Shams University Hospitals

NCT07088081 is registered in ClinicalTrials.gov with Ain Shams University as lead sponsor.

NCT NCT07088081
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07088081 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of Efficacy and Safety of Immune Check Point Inhibitors in Hepatocellular Carcinoma Patients in Ain Shams University Hospitals
Lead sponsor
Ain Shams University
Phase
Observational
Overall status
Enrolling by invitation
Start date
June 1, 2025
Completion date
July 31, 2026
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

atezolizumab and bevacizumab in hepatocellular carcinoma, durvalumab, hcc - hepatocellular carcinoma, immune checkpoint inhibitor-induced dermatitis, immune checkpoint therapy, immunotherapy